Back to top

Lexicon (LXRX) Completes Patient Randomization in Key Phase 3 Trial

Lexicon (LXRX) Completes Patient Randomization in Key Phase 3 Trial

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Lexicon Pharmaceuticals, Inc. (LXRX)